$24.32▲ 0.25 (1.04%)
Real-time prices · US MarketsHealthy balance sheet and financial position.
low return on equity (-91%).
Quality
1.6
Health
7.7
Growth
4.1
Valuation
6.5
Sentiment
7.3
Analyst Target
$38.75
▲ +59.3% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-7.3×
next 12 months est.
Market Cap
$3.1B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-90.8%
return on equity
Beta
0.81
vs S&P 500
52-Week Range
$12 — $32
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Arcus Biosciences, Inc. right now?
Arcus Biosciences, Inc.'s Q·Score is 5.2/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: low return on equity (-91%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for RCUS?
The consensus price target for RCUS is $38.75, based on ratings from 12 Wall Street analysts. This is 59.3% above the current price of $24.32. Price targets are forward-looking estimates and not guarantees of future performance.
Is RCUS overvalued or undervalued?
Arcus Biosciences, Inc. (RCUS) scores in line with sector averages on valuation metrics. The consensus analyst price target of $38.75 is 59% above the current price.
When does Arcus Biosciences, Inc. report its next earnings?
Arcus Biosciences, Inc.'s next earnings report is expected on approximately October 27, 2026.
What is Arcus Biosciences, Inc.'s profit margin?
Arcus Biosciences, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
Is Arcus Biosciences, Inc.'s revenue growing?
Arcus Biosciences, Inc. is reporting revenue declining 74.4% year-over-year.
How much debt does Arcus Biosciences, Inc. have?
Arcus Biosciences, Inc. has a debt-to-equity ratio of 0.51×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 3.82×, indicating comfortable short-term liquidity.